Mednax Inc Stock Alpha and Beta Analysis

MD Stock  USD 14.96  0.21  1.42%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Mednax Inc. It also helps investors analyze the systematic and unsystematic risks associated with investing in Mednax over a specified time horizon. Remember, high Mednax's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Mednax's market risk premium analysis include:
Beta
1.72
Alpha
0.3
Risk
3.58
Sharpe Ratio
0.15
Expected Return
0.53
Please note that although Mednax alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., Dow Jones Industrial index.) So in this particular case, Mednax did 0.30  better than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of Mednax Inc stock's relative risk over its benchmark. Mednax Inc has a beta of 1.72  . As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Mednax will likely underperform. At present, Mednax's Enterprise Value Multiple is projected to increase significantly based on the last few years of reporting.

Mednax Quarterly Cash And Equivalents

21.18 Million

Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out Mednax Backtesting, Mednax Valuation, Mednax Correlation, Mednax Hype Analysis, Mednax Volatility, Mednax History and analyze Mednax Performance.

Mednax Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Mednax market risk premium is the additional return an investor will receive from holding Mednax long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Mednax. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Mednax's performance over market.
α0.30   β1.72

Mednax expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Mednax's Buy-and-hold return. Our buy-and-hold chart shows how Mednax performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

Mednax Market Price Analysis

Market price analysis indicators help investors to evaluate how Mednax stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Mednax shares will generate the highest return on investment. By understating and applying Mednax stock market price indicators, traders can identify Mednax position entry and exit signals to maximize returns.

Mednax Return and Market Media

The median price of Mednax for the period between Tue, Aug 27, 2024 and Mon, Nov 25, 2024 is 12.08 with a coefficient of variation of 14.03. The daily time series for the period is distributed with a sample standard deviation of 1.74, arithmetic mean of 12.42, and mean deviation of 1.42. The Stock received substential amount of media coverage during this period.
 Price Growth (%)  
       Timeline  
1
Disposition of 11100 shares by Swift James D of Mednax at 10.79 subject to Rule 16b-3
08/30/2024
2
Insider Trading
10/01/2024
3
Pediatrix Medical Group 2024 Third Quarter Conference CallWebcast Scheduled for Friday, November 1, 2024
10/16/2024
4
Amazon and Chevron lead morning market cap stock movers on Friday
11/01/2024
5
Acquisition by C Richards of 45308 shares of Mednax subject to Rule 16b-3
11/04/2024
6
Pediatrix Medical Group, Inc. Shares Fly 27 percent But Investors Arent Buying For Growth
11/06/2024
7
Mizuho Forecasts Strong Price Appreciation for Pediatrix Medical Group Stock
11/07/2024
8
Disposition of 27600 shares by Mark Ordan of Mednax at 15.35 subject to Rule 16b-3
11/13/2024
9
Pediatrix Medical Group Downgraded by StockNews.com to Hold
11/22/2024

About Mednax Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Mednax or other stocks. Alpha measures the amount that position in Mednax Inc has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
 2021 2022 2023 2024 (projected)
Days Sales Outstanding57.6354.9351.2173.79
PTB Ratio2.571.390.920.87

Mednax Upcoming Company Events

As portrayed in its financial statements, the presentation of Mednax's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Mednax's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Mednax's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Mednax. Please utilize our Beneish M Score to check the likelihood of Mednax's management manipulating its earnings.
16th of February 2024
Upcoming Quarterly Report
View
7th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
16th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Build Portfolio with Mednax

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Mednax technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Mednax technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Mednax trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...